Literature DB >> 23993262

Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura.

Nivas Balasubramaniyam1, Dhaval Kolte, Chandrasekar Palaniswamy, Kiran Yalamanchili, Wilbert S Aronow, John A McClung, Sahil Khera, Sachin Sule, Stephen J Peterson, William H Frishman.   

Abstract

BACKGROUND: Despite the widespread availability of plasmapheresis as a therapy, thrombotic thrombocytopenic purpura is associated with significant morbidity and mortality. There is a paucity of data on the predictors of poor clinical outcome in this population. Acute myocardial infarction is a recognized complication of thrombotic thrombocytopenic purpura. Little is known about the magnitude of this problem, its risk factors, and its influence on mortality in patients hospitalized with thrombotic thrombocytopenic purpura.
METHODS: We used the 2001-2010 Nationwide Inpatient Sample database to identify patients aged ≥18 years with the diagnosis of thrombotic thrombocytopenic purpura (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 446.6) who also received therapeutic plasmapheresis (ICD-9-CM code 99.71) during the hospitalization. Patients with acute myocardial infarction were identified using the Healthcare Cost and Utilization Project Clinical Classification Software code 100. Stepwise logistic regression was used to determine independent predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura patients.
RESULTS: Among the 4032 patients (mean age 47.5 years, 67.7% women, and 36.9% white) with thrombotic thrombocytopenic purpura who also underwent plasmapheresis, in-hospital mortality was 11.1%. Independent predictors of increased in-hospital mortality were older age (odds ratio [OR] 1.03; 95% confidence interval [CI], 1.02-1.04; P <.001), acute myocardial infarction (OR 1.89; 95% CI, 1.24-2.88; P = .003), acute renal failure (OR 2.75; 95% CI, 2.11-3.58; P <.001), congestive heart failure (OR 1.66; 95% CI, 1.17-2.34; P = .004), acute cerebrovascular disease (OR 2.68; 95% CI, 1.87-3.85; P <.001), cancer (OR 2.49; 95% CI, 1.83-3.40; P <.001), and sepsis (OR 2.59; 95% CI, 1.88-3.59; P <.001). Independent predictors of acute myocardial infarction were older age (OR 1.03; 95% CI, 1.02-1.04; P <.001), smoking (OR 1.60; 95% CI, 1.14-2.24; P = .007), known coronary artery disease (OR 2.59; 95% CI, 1.76-3.81; P <.001), and congestive heart failure (OR 2.40; 95% CI, 1.71-3.37; P <.001).
CONCLUSION: In this large national database, patients with thrombotic thrombocytopenic purpura had an in-hospital mortality rate of 11.1% and an acute myocardial infarction rate of 5.7%. Predictors of in-hospital mortality were older age, acute myocardial infarction, acute renal failure, congestive heart failure, acute cerebrovascular disease, cancer, and sepsis. Predictors of acute myocardial infarction were older age, smoking, known coronary artery disease, and congestive heart failure.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Mortality; Thrombotic thrombocytopenic purpura

Mesh:

Year:  2013        PMID: 23993262     DOI: 10.1016/j.amjmed.2013.03.021

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement?

Authors:  Lara Zafrani; Lene Russell; Elie Azoulay
Journal:  Intensive Care Med       Date:  2018-06-04       Impact factor: 17.440

2.  Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels.

Authors:  Qianyi Ma; Paula M Jacobi; Brian T Emmer; Colin A Kretz; Ayse Bilge Ozel; Beth McGee; Chava Kimchi-Sarfaty; David Ginsburg; Jun Z Li; Karl C Desch
Journal:  Blood Adv       Date:  2017-06-19

3.  Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.

Authors:  Jingrui Sui; Wenjing Cao; Konstantine Halkidis; Mohammad S Abdelgawwad; Nicole K Kocher; Bryan Guillory; Lance A Williams; Radhika Gangaraju; Marisa B Marques; X Long Zheng
Journal:  Blood Adv       Date:  2019-12-23

4.  Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.

Authors:  Yinan Xu; Chengyuan Gu; Ruju Wang; Jiaqian Qi; Jun Wang; Tingbo Jiang; Min Jiang; Depei Wu; Tao You; Jianhong Fu
Journal:  J Clin Lab Anal       Date:  2022-06-11       Impact factor: 3.124

5.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

6.  Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.

Authors:  Ruinan Lu; Jingrui Sui; X Long Zheng
Journal:  Blood Adv       Date:  2020-11-10

7.  Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012.

Authors:  Ruchika Goel; Karen E King; Clifford M Takemoto; Paul M Ness; Aaron A R Tobian
Journal:  Transfusion       Date:  2016-04-15       Impact factor: 3.157

Review 8.  The standard of care for immune thrombotic thrombocytopenic purpura today.

Authors:  X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-06-30       Impact factor: 16.036

9.  Differences in the Prevalence of Obesity, Smoking and Alcohol in the United States Nationwide Inpatient Sample and the Behavioral Risk Factor Surveillance System.

Authors:  Elie S Al Kazzi; Brandyn Lau; Tianjing Li; Eric B Schneider; Martin A Makary; Susan Hutfless
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

10.  Thrombotic thrombocytopenic purpura presenting as acute coronary syndrome.

Authors:  Jason Aboudi Mouabbi; Rami Zein; Zyad Kafri; Ayad Al-Katib; Tarik Hadid
Journal:  Clin Case Rep       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.